Investor Relations

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ELAD Phase IIB Data Presented at ILTS
Data from Phase 2b Study of ELAD® Presented at International Liver Transplant Society Meeting.
View HTML
Toggle Summary Vital Therapies Prices Initial Public Offering
Vital Therapies Prices Initial Public Offering Vital Therapies Prices Initial Public Offering SAN DIEGO, CA--(Marketwired - Apr 16, 2014) - Vital Therapies, Inc. ( NASDAQ : VTL ), a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure, today
View HTML
Toggle Summary Vital Therapies Announces Upcoming First Quarter Financial Results Conference Call With Webcast
SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its first quarter 2017 financial results after the market closes on Tuesday, May
View HTML
Toggle Summary Liver device helps man survive until transplant
Liver device helps man survive until transplant
View HTML
Toggle Summary Three-year follow-up data confirm safety and survival benefit in Chinese liver failure patients treated with ELAD®
Three-year follow-up data confirm safety and survival benefit in Chinese liver failure patients treated with ELAD ®
View HTML
Toggle Summary Vital new hope for Liver failure
Vital new hope for Liver failure
View HTML
Toggle Summary Vital Therapies Announces Upcoming Fourth Quarter and Full Year 2015 Financial Results Conference Call With Webcast
SAN DIEGO, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, will release its fourth quarter and full year 2015 financial results after the market closes on Tuesday,
View HTML
Toggle Summary Vital Therapies Announces Upcoming Second Quarter Financial Results Conference Call With Webcast
SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its second quarter 2017 financial results after the market closes on Thursday,
View HTML
Toggle Summary Vital Therapies Expands SILVER Trial to Saudi Arabia
Vital Therapies Expands SILVER Trial to Saudi Arabia
View HTML
Toggle Summary Vital Therapies Plans Phase III Trials for September
Vital Therapies Plans Phase III Trials for September
View HTML